$ANAB
ANAPTYSBIO, INC Stock $anab

$anab Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000137005322000043 Filed on August 08, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$1.293M	$1.216M	$970.0K
YoY Change	-93.81%	-95.95%	-91.38%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.862M	$8.171M	$10.20M
YoY Change	63.14%	55.76%	88.25%
% of Gross Profit
Research & Development	$22.06M	$20.84M	$22.52M
YoY Change	-0.71%	-17.66%	-6.9%
% of Gross Profit
Depreciation & Amortization	$166.0K	$163.0K	$162.0K
YoY Change	-1.78%	5.16%	29.6%
% of Gross Profit
Operating Expenses	$30.93M	$29.02M	$32.72M
YoY Change	11.84%	-5.06%	10.51%
Operating Profit	-$29.63M	-$27.80M	-$31.75M
YoY Change	338.16%	5115.57%	72.92%
Interest Expense	$2.262M	$1.107M	$342.0K
YoY Change	3434.38%	964.42%	75.38%
% of Operating Profit
Other Income/Expense, Net	-$3.869M	-$4.755M	-$4.506M
YoY Change	-4088.66%	-4672.12%	-2375.76%
Pretax Income	-$33.50M	-$32.55M	-$36.26M
YoY Change	402.58%	7488.34%	99.64%
Income Tax
% Of Pretax Income
Net Earnings	-$33.50M	-$32.55M	-$36.26M
YoY Change	402.58%	7488.34%	99.61%
Net Earnings / Revenue	-2591.03%	-2677.14%	-3737.63%
Basic Earnings Per Share	-$1.18	-$1.15	-$1.31
Diluted Earnings Per Share	-$1.18	-$1.15	-$1.31
COMMON SHARES
Basic Shares Outstanding	28.24M shares	28.20M shares	27.71M shares
Diluted Shares Outstanding	28.29M shares	28.20M shares	27.71M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$443.0M	$442.2M	$505.6M
YoY Change	18.42%	13.13%	32.93%
Cash & Equivalents	$58.55M	$71.70M	$166.4M
Short-Term Investments	$384.4M	$370.5M	$339.2M
Other Short-Term Assets	$6.298M	$9.625M	$5.869M
YoY Change	-46.71%	46.54%	4.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$450.4M	$452.8M	$512.4M
YoY Change	16.5%	13.75%	32.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.972M	$2.059M	$2.162M
YoY Change	-18.28%	-17.24%	23.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$147.5M	$130.0M	$91.20M
YoY Change	867.79%	2270.26%	1184.44%
Other Assets	$256.0K	$256.0K	$256.0K
YoY Change	-0.78%	-0.78%	-46.33%
Total Long-Term Assets	$168.1M	$151.0M	$112.8M
YoY Change	345.89%	429.81%	1114.17%
TOTAL ASSETS
Total Short-Term Assets	$450.4M	$452.8M	$512.4M
Total Long-Term Assets	$168.1M	$151.0M	$112.8M
Total Assets	$618.5M	$603.8M	$625.2M
YoY Change	45.76%	41.56%	57.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.006M	$1.587M	$2.481M
YoY Change	-47.42%	-61.32%	1.18%
Accrued Expenses	$16.45M	$16.71M	$15.76M
YoY Change	16.9%	4.74%	33.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$21.06M	$19.87M	$19.78M
YoY Change	0.83%	-3.61%	36.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$319.8M	$279.7M	$274.6M
YoY Change	1512.16%	1283.0%
Total Long-Term Liabilities	$319.8M	$279.7M	$274.6M
YoY Change	1512.16%	1283.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.06M	$19.87M	$19.78M
Total Long-Term Liabilities	$319.8M	$279.7M	$274.6M
Total Liabilities	$340.9M	$299.5M	$294.4M
YoY Change	737.0%	633.49%	1930.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$424.1M	-$390.6M	-$358.0M
YoY Change	46.63%	38.23%	26.9%
Common Stock	$28.00K	$28.00K	$28.00K
YoY Change	3.7%	3.7%	3.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$277.6M	$304.3M	$330.7M
YoY Change
Total Liabilities & Shareholders Equity	$618.5M	$603.8M	$625.2M
YoY Change	45.76%	41.56%	57.7%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$33.50M	-$32.55M	-$36.26M
YoY Change	402.58%	7488.34%	99.61%
Depreciation, Depletion And Amortization	$166.0K	$163.0K	$162.0K
YoY Change	-1.78%	5.16%	29.6%
Cash From Operating Activities	-$17.75M	-$24.15M	-$21.01M
YoY Change	153.31%	-351.87%	-9.44%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$78.00K	$55.00K
YoY Change	-70.93%	-90.93%	-82.65%
Acquisitions
YoY Change
Other Investing Activities	-$32.38M	-$70.92M	-$312.9M
YoY Change	-394.11%	-282.68%	-648.39%
Cash From Investing Activities	-$32.43M	-$71.00M	-$312.9M
YoY Change	-399.23%	-287.03%	-651.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$4.844M
YoY Change			2800.6%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	37.03M	432.0K	$4.609M
YoY Change	15263.9%	-21.6%	2659.88%
NET CHANGE
Cash From Operating Activities	-17.75M	-24.15M	-$21.01M
Cash From Investing Activities	-32.43M	-71.00M	-$312.9M
Cash From Financing Activities	37.03M	432.0K	$4.609M
Net Change In Cash	-13.15M	-94.71M	-$329.3M
YoY Change	-422.88%	-296.91%	-1077.43%
FREE CASH FLOW
Cash From Operating Activities	-$17.75M	-$24.15M	-$21.01M
Capital Expenditures	-$50.00K	-$78.00K	$55.00K
Free Cash Flow	-$17.70M	-$24.07M	-$21.07M
YoY Change	158.96%	-330.39%	-10.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001370053
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20220630#CollaborationRevenueMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20220630#CollaborationRevenueMember
CY2021Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20220630#CollaborationRevenueMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20220630#CollaborationRevenueMember
	dei	Document Type DocumentType	10-Q
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37985
	dei	Entity Registrant Name EntityRegistrantName	ANAPTYSBIO, INC
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3828755
	dei	Entity Address Address Line1 EntityAddressAddressLine1	10770 Wateridge Circle
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	362-6295
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	ANAB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28239212	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71701000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	495729000	usd
CY2022Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	1033000	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	876000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	370450000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	52368000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9625000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4903000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	452809000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	553876000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2059000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2283000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18739000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19558000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	129985000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	67097000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	256000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	256000	usd
CY2022Q2	us-gaap	Assets Assets	603848000	usd
CY2021Q4	us-gaap	Assets Assets	643070000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1587000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1741000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16714000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12853000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1570000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1505000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	19871000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16099000	usd
CY2022Q2	anab	Advance Future Royalties Liability Noncurrent AdvanceFutureRoyaltiesLiabilityNoncurrent	261019000	usd
CY2021Q4	anab	Advance Future Royalties Liability Noncurrent AdvanceFutureRoyaltiesLiabilityNoncurrent	251093000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18652000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19450000	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28231000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28231000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27647000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27647000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	28000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	28000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	698701000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	678575000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3861000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-422000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-390562000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-321753000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	304306000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	356428000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	603848000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	643070000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1216000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30027000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2186000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41274000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20844000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25314000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43360000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49499000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8171000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5246000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18374000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10669000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	29015000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	30560000	usd
	us-gaap	Operating Expenses OperatingExpenses	61734000	usd
	us-gaap	Operating Expenses OperatingExpenses	60168000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-27799000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-533000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-59548000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18894000	usd
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	1107000	usd
CY2021Q2	us-gaap	Interest Income Other InterestIncomeOther	104000	usd
	us-gaap	Interest Income Other InterestIncomeOther	1449000	usd
	us-gaap	Interest Income Other InterestIncomeOther	299000	usd
CY2022Q2	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	5868000	usd
CY2021Q2	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	0	usd
	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	10722000	usd
	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	0	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4755000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	104000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9261000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	302000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-32554000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-429000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-68809000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-18592000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1427000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-65000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3439000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-172000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33981000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-494000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72248000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18764000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.15
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.15
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28204000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28204000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27391000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27391000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27960000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27960000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27377000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27377000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	356428000	usd
CY2022Q1	anab	Stock Issued During Period Value Options And Employee Stock Purchase Plan StockIssuedDuringPeriodValueOptionsAndEmployeeStockPurchasePlan	4844000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7742000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2012000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36255000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	330747000	usd
CY2022Q2	anab	Stock Issued During Period Value Options And Employee Stock Purchase Plan StockIssuedDuringPeriodValueOptionsAndEmployeeStockPurchasePlan	882000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6658000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1427000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-32554000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	304306000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	396731000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	167000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3315000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-107000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18163000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	381943000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	592000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3690000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-65000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-429000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	385731000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-68809000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-18592000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	325000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	285000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	14400000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7005000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-293000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	819000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	751000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-10722000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	157000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	642000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5339000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3235000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3611000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	772000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-733000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-250000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45161000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13613000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	494795000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	9734000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	111020000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	105604000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1180000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-383908000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	94690000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5709000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	721000	usd
	anab	Advance Future Royalty And Milestone Payments AdvanceFutureRoyaltyAndMilestonePayments	666000	usd
	anab	Advance Future Royalty And Milestone Payments AdvanceFutureRoyaltyAndMilestonePayments	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5041000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	721000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-424028000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	81798000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	495729000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	250516000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71701000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	332314000	usd
	anab	Noncash Advance Future Royalties Issuance Costs Incurred But Not Yet Paid NoncashAdvanceFutureRoyaltiesIssuanceCostsIncurredButNotYetPaid	128000	usd
	anab	Noncash Advance Future Royalties Issuance Costs Incurred But Not Yet Paid NoncashAdvanceFutureRoyaltiesIssuanceCostsIncurredButNotYetPaid	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	20685000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	89000	usd
	anab	Receivables For Stock Options Exercised ReceivablesForStockOptionsExercised	17000	usd
	anab	Receivables For Stock Options Exercised ReceivablesForStockOptionsExercised	38000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Description of the Business<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AnaptysBio, Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the state of Delaware in November 2005. We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. Our proprietary clinical stage pipeline includes imsidolimab, our anti-IL-36R antibody, previously referred to as ANB019, for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, and moderate-to-severe hidradenitis suppurativa; rosnilimab, our anti-PD-1 agonist program, previously referred to as ANB030, for the treatment of moderate-to-severe alopecia areata; and ANB032, our anti-BTLA agonist program, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. We have also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly) GSK4057190), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386). We currently generate revenue from milestones and royalties achieved under our collaborative research and development arrangements. Our antibody pipeline has been developed using our proprietary somatic hypermutation, or SHM platform, which uses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have devoted our primary effort to research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, royalty monetization, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next twelve months from the issuance of our consolidated financial statements. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div>
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7306000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7205000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5247000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4922000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2059000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2283000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3200000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4177000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	802000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	569000	usd
CY2022Q2	anab	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	12581000	usd
CY2021Q4	anab	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	7953000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	131000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	154000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16714000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12853000	usd
CY2021Q4	anab	Advance Future Royalties Liabilities AdvanceFutureRoyaltiesLiabilities	251093000	usd
	anab	Advance Future Royalties Issuance Costs AdvanceFutureRoyaltiesIssuanceCosts	130000	usd
	anab	Amortization Of Advance Future Royalties Issuance Costs AmortizationOfAdvanceFutureRoyaltiesIssuanceCosts	32000	usd
	anab	Advance Future Royalty And Milestone Payments AdvanceFutureRoyaltyAndMilestonePayments	666000	usd
	anab	Noncash Interest Expense Recognized NoncashInterestExpenseRecognized	10690000	usd
CY2022Q2	anab	Advance Future Royalties Liabilities AdvanceFutureRoyaltiesLiabilities	261019000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	507580000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	57000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3710000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	503927000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	119680000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	217000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	119465000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	464217000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	3710000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	464217000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	3710000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	108694000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	217000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	108694000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	217000	usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	3700000	usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	200000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28231344	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28231344	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	29.94
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	563147	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3802921	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	969643	shares
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8778854	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3460295	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.84
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M1D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	42987000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1212920	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.50
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	307147	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	30.98
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3802921	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.88
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M19D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4989000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1755799	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	36.40
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M18D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3364000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6658000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3690000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14400000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7005000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.040
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y2M12D
	us-gaap	Operating Lease Cost OperatingLeaseCost	1239000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	886000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1147000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	465000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1169000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2386000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2457000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2531000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2607000	usd
CY2022Q2	anab	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	13239000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	24389000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4167000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	20222000	usd

Files In Submission

Name	View Source	Status
0001370053-22-000043-index-headers.html	Edgar Link	pending
0001370053-22-000043-index.html	Edgar Link	pending
0001370053-22-000043.txt	Edgar Link	pending
0001370053-22-000043-xbrl.zip	Edgar Link	pending
anab-20220630.htm	Edgar Link	pending
anab-20220630.xsd	Edgar Link	pending
anab-20220630_g1.jpg	Edgar Link	pending
anab-6302022x10qxexx311.htm	Edgar Link	pending
anab-6302022x10qxexx312.htm	Edgar Link	pending
anab-6302022x10qxexx321.htm	Edgar Link	pending
anab-6302022x10qxexx322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
anab-20220630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
anab-20220630_def.xml	Edgar Link	unprocessable
anab-20220630_lab.xml	Edgar Link	unprocessable
anab-20220630_pre.xml	Edgar Link	unprocessable
anab-20220630_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANAB
ANAPTYSBIO, INC Stock $anab

2022 Q3 Form 10-Q Financial Statement

#000137005322000043 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB ANAPTYSBIO, INC Stock $anab

2022 Q3 Form 10-Q Financial Statement

#000137005322000043 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB
ANAPTYSBIO, INC Stock $anab